Mr Marc N Casper, president and CEO, Thermo Fisher Scientific, USA
Thermo Fisher Scientific, a global player in serving science has revenues of about $12 billion, with approximately 39,000 employees serving customers within pharmaceutical and biotech companies, hospitals and clinical diagnostic labs, universities, research institutions and government agencies, as well as environmental and process control industries. With a revenue of $1.8 billion coming from emerging markets and Asia Pacific region-growing at the rate of 20 percent-the company has various strategies in place for the region, such as scaling up its commercial teams to drive growth, optimizing supply chain, service and commercial operations to differentiate the customer experience, continuing to invest in localized technology development and expanding low-cost region manufacturing footprint to take it to new heights.
In an exclusive interview with BioSpectrum, Mr Marc N Casper, president and chief executive officer of Thermo Fisher Scientific, shares the company's strategies on investments related to research and development, acquisitions, growth for the emerging markets, pricing and regulatory issues.
Thermo fisher has increased its investments on acquisitions and purchasing property from $837 million in 2009 to $6 billion in 2011. How much have you set aside towards investments in 2012 for similar activities?
Actually, since 2009 we have generated about $10 billion in capital from our free cash flow and deployed about $7 billion for acquisitions. While we cannot disclose what acquisitions we may be making in the future, Thermo Fisher has a proven track record of achieving our operating income objectives through revenue and cost synergies and tax efficiencies.
Will your focus now be more on acquisitions?
Thermo Fisher looks at organic as well as inorganic routes to grow. We have been investing in acquisitions that help us to enhance our offering to our customers and increase our access to growing markets worldwide.